Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
Ganser
A
A
Department of Hematology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
Ottmann
O G
OG
Hoelzer
D
D
D000741:Anemia, Aplastic / Q000145:classification / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001855:Bone Marrow Diseases / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D004359:Drug Therapy, Combination; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007377:Interleukin-3 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count / Q000187:drug effects; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000628:therapy; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy
D007155:Immunologic Factors; D007377:Interleukin-3; D016178:Granulocyte-Macrophage Colony-Stimulating Factor